Management of QTc Prolongation in Patients Receiving Diazepam

Critical Risk Assessment

A QTc of 595 ms places the patient at extremely high risk for torsades de pointes (TdP) and sudden cardiac death, according to the American Heart Association 1
The risk of adverse cardiac events increases significantly when QTc exceeds 500 ms, as stated by the American College of Cardiology 2

Benzodiazepines, including diazepam, do not appear on lists of QT-prolonging medications and do not have significant effects on cardiac repolarization, as reported by the European Society of Cardiology 2
Unlike many other sedatives and antiemetics, benzodiazepines are not associated with QTc prolongation, according to the European Heart Journal 3 and the American Society for Clinical Pharmacology and Therapeutics 4

Immediately check and correct electrolyte abnormalities, particularly potassium and magnesium levels, as recommended by the American Heart Association 5 and the National Comprehensive Cancer Network 6
Hypokalemia and hypomagnesemia must be corrected before any medication decisions, according to the National Comprehensive Cancer Network 6
Review all current medications and discontinue any QT-prolonging drugs if clinically feasible, as suggested by the American College of Clinical Pharmacy 4

Female gender, bradycardia, congestive heart failure, and baseline QT prolongation are additional risk factors, as identified by the American College of Cardiology 2 and the European Society of Cardiology 7
Patients with structural heart disease require extra caution, according to the European Heart Journal 3

Avoid Class III antiarrhythmics (amiodarone, sotalol, dofetilide) in patients with QTc >500 ms, as recommended by the European Society of Cardiology 3 and the National Comprehensive Cancer Network 6
Certain antiemetics (5-HT3 receptor antagonists, domperidone, metoclopramide) should also be avoided, according to the American College of Clinical Pharmacy 2 and the European Society of Cardiology 7

Obtain baseline ECG and repeat after electrolyte correction, as recommended by the National Comprehensive Cancer Network 6 and the American Heart Association 1
Monitor potassium and magnesium levels periodically during treatment, according to the American Heart Association 5 and the European Society of Cardiology 7